Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae (CAPITIS)
Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic Urinary Tract Infections Due to Extended-spectrum Β-lactamase (ESBL)-producing Escherichia Coli or Klebsiella Pneumoniae - (CAPITIS Study)
Sponsor: Universidad del Norte
Suspended
Low admission of patients with the condition to the hospital because it is a reference center for care of the SARS-CoV-2 pandemic
A PHASE4 clinical study on Carbapenem and Clinical Trial, this trial is suspended. The trial is conducted by Universidad del Norte and has accumulated 7 data snapshots since 2019. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
7 versions recorded-
Jan 2025 — Present [monthly]
Suspended PHASE4
Status: Unknown → Suspended
-
Sep 2024 — Jan 2025 [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Oct 2021 — Jul 2024 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE4
▶ Show 2 earlier versions
-
May 2019 — Jan 2021 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Apr 2019 — May 2019 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Universidad del Norte
For direct contact, visit the study record on ClinicalTrials.gov .